Sarcoma  >>  Jemperli (dostarlimab-gxly)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jemperli (dostarlimab-gxly) / GSK
STARKAP, NCT05646082: Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma

Recruiting
1
20
Europe
Dostarlimab in Combination Antiretroviral Therapy
Imperial College London
Refractory HIV Associated Kaposi Sarcoma
05/24
09/25
SCOOP, NCT04544995 / 2020-002359-39: Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors

Suspended
1
116
Europe, RoW
Niraparib, Dostarlimab
GlaxoSmithKline
Neoplasms
09/28
04/29

Download Options